A registry study on the actual situation for COVID-19 outpatients in Japan -ANTARES STUDY- - A registry study on the actual situation for COVID-19 outpatients in Japan -ANTARES STUDY

Shionogi & Co., Ltd.0 个研究点目标入组 10,000 人开始时间: 2023年11月8日最近更新: 2024年4月23日

适应症

试验速览

暂无简介。

•Patients who meet at least one of the following criteria are excluded. 1) Patients who are judged by their principal (or sub-) investigator from each site to ineligible to participate in this study 2) Hospitalized patients or patients who are treated COVID-19 in hospital 3) Patients who received anti-SARS-Cov-2 drugs within 30 days prior to enrollment 4) Patients who receiving injectable anti-SARS-CoV-2 drugs, or drugs with reported effects on SARS-CoV-2 such as favipiravir and ivermectin at the date of enrollment (however, molnupiravir, nirmatrelvir/ ritonavir and ensitrelvir can be administered) 5) Patients who have previously participated in this study 6) Patients who are currently participating in clinical trials or interventional prospective studies, not limited to COVID-19 related study 7) Patients who have not received 30 days of the last dose or 5 times the half-life period of the investigational study drug or unapproved drug

发起方

Shionogi & Co., Ltd.